• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

激素初治、激素治疗及去势抵抗性转移性前列腺癌患者临床进展过程中前列腺组织的形态学和功能改变。

Morphological and functional alterations of the prostate tissue during clinical progression in hormonally-naïve, hormonally-treated and castration-resistant patients with metastatic prostate cancer.

作者信息

Korček Michal, Sekerešová Monika, Makarevich Alexander V, Gavurová Helena, Olexíková Lucia, Pivko Juraj, Barreto Lenka

机构信息

Department of Urology, Faculty Hospital Nitra, 94901 Nitra, Slovak Republic.

Department of Pathology, Faculty Hospital Nitra, 94901 Nitra, Slovak Republic.

出版信息

Oncol Lett. 2020 Nov;20(5):201. doi: 10.3892/ol.2020.12064. Epub 2020 Sep 8.

DOI:10.3892/ol.2020.12064
PMID:32963607
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7491063/
Abstract

Since commony used tools in oncological practice for the diagnosis of castration-resistent prostatic acinar adenocarcinoma are based on clinical criteria, such as castrate testosterone level, continuous rise in serum prostate-specific antigen, progression of preexisting disease or appearance of new metastases, it is important to identify reliable histopathological markers for the identification of this disease. Therefore, the aim of the present study was to determine the association between results from histological analysis, ultrastructural analysis and apoptosis in the prostate of patients with metastatic acinar prostatic adenocarcinoma (mPC). Patients were treated with androgen deprivation therapy (ADT), abiraterone acetate (Abi) therapy or received no treatment. Prostate tissue samples were divided into four groups as follows: i) Group 1, tissues from patients with benign prostatic hyperplasia (adenocarcinoma negative); ii) group 2, tissues from patients with metastatic hormone naïve prostate cancer; iii) group 3, tissues from patients with mPC treated with ADT; and iv) group 4, tissues from patients with metastatic castration-resistant prostate cancer treated with ADT and Abi. Immunohistochemical, terminal deoxynucleotidyl-transferase-mediated dUTP nick end labelling (TUNEL) and ultrastructural assays using light, fluorescence and transmission electron microscopy, respectively, were used to analyze prostate tissue samples. The results demonstrated that ADT and Abi therapy caused histological and ultrastructural changes in prostate tissues. In groups 3 and 4, benign and malignant tissues were affected by the hormonal therapy. Histologically, the malignant epithelium after ADT therapy in groups 3 and 4 presented with a loss of glandular architecture, nuclear and nucleolar shrinkage, chromatin condensation and cytoplasmic clearing. At the ultrastructural level, compact hypertrophic and hyperchromatic nuclei with numerous invaginations were observed in groups 2, 3 and 4. In addition, the incidence of abnormal mitochondria in malignant cells of these groups was high. Group 4 was characterized by the presence of malignant mesenchyme-like cells in the prostatic stroma, arranged in small groups surrounded by collagen fibrils. Furthermore, the cytoplasm of these cells contained filaments. A decrease in the number of apoptotic cells using TUNEL assays in the examined samples was observed with increasing disease progression. The findings from the present study suggest that the duration of treatment with ADT and progression of the disease were associated with apoptosis dysregulation.

摘要

由于肿瘤学实践中用于诊断去势抵抗性前列腺腺泡腺癌的常用工具基于临床标准,如去势睾酮水平、血清前列腺特异性抗原持续升高、原有疾病进展或新转移灶出现,因此识别可靠的组织病理学标志物以诊断该疾病很重要。因此,本研究的目的是确定转移性腺泡前列腺癌(mPC)患者前列腺组织学分析、超微结构分析结果与细胞凋亡之间的关联。患者接受雄激素剥夺治疗(ADT)、醋酸阿比特龙(Abi)治疗或未接受治疗。前列腺组织样本分为以下四组:i)第1组,来自良性前列腺增生患者的组织(腺癌阴性);ii)第2组,来自未经激素治疗的转移性前列腺癌患者的组织;iii)第3组,来自接受ADT治疗的mPC患者的组织;iv)第4组,来自接受ADT和Abi治疗的转移性去势抵抗性前列腺癌患者的组织。分别使用免疫组织化学、末端脱氧核苷酸转移酶介导的dUTP缺口末端标记(TUNEL)以及光镜、荧光显微镜和透射电子显微镜进行超微结构分析,以分析前列腺组织样本。结果表明,ADT和Abi治疗导致前列腺组织发生组织学和超微结构变化。在第3组和第4组中,良性和恶性组织均受到激素治疗的影响。组织学上,第3组和第4组ADT治疗后的恶性上皮呈现腺泡结构丧失、细胞核和核仁缩小、染色质浓缩以及细胞质清亮。在超微结构水平上,第2、3和4组观察到细胞核致密肥大、染色质增多且有大量内陷。此外,这些组恶性细胞中异常线粒体的发生率很高。第4组的特征是前列腺基质中存在恶性间充质样细胞,成小群排列,周围有胶原纤维。此外,这些细胞的细胞质中含有细丝。随着疾病进展,在所检查样本中使用TUNEL分析观察到凋亡细胞数量减少。本研究结果表明,ADT治疗持续时间和疾病进展与细胞凋亡失调有关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5534/7491063/416b2b49bd0a/ol-20-05-12064-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5534/7491063/2995eb7c4351/ol-20-05-12064-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5534/7491063/48ee9c5ef14e/ol-20-05-12064-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5534/7491063/416b2b49bd0a/ol-20-05-12064-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5534/7491063/2995eb7c4351/ol-20-05-12064-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5534/7491063/48ee9c5ef14e/ol-20-05-12064-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5534/7491063/416b2b49bd0a/ol-20-05-12064-g02.jpg

相似文献

1
Morphological and functional alterations of the prostate tissue during clinical progression in hormonally-naïve, hormonally-treated and castration-resistant patients with metastatic prostate cancer.激素初治、激素治疗及去势抵抗性转移性前列腺癌患者临床进展过程中前列腺组织的形态学和功能改变。
Oncol Lett. 2020 Nov;20(5):201. doi: 10.3892/ol.2020.12064. Epub 2020 Sep 8.
2
Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.新诊断转移性去势敏感性前列腺癌患者中阿比特龙联合泼尼松添加到雄激素剥夺治疗后的患者报告结局(LATITUDE):一项国际性、随机 3 期临床试验。
Lancet Oncol. 2018 Feb;19(2):194-206. doi: 10.1016/S1470-2045(17)30911-7. Epub 2018 Jan 8.
3
Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis.醋酸阿比特龙与多西他赛联合雄激素剥夺疗法治疗高危和转移性激素初治前列腺癌的比较:系统评价和网络荟萃分析。
Eur Urol. 2018 Jun;73(6):834-844. doi: 10.1016/j.eururo.2017.10.002. Epub 2017 Oct 14.
4
Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.在 GETUG-AFU 15 期 3 期试验中,对于转移性去势敏感前列腺癌,在雄激素剥夺治疗联合或不联合多西他赛治疗的男性患者中,进展后接受的治疗的抗癌活性和耐受性。
Eur Urol. 2018 May;73(5):696-703. doi: 10.1016/j.eururo.2017.09.022. Epub 2017 Oct 23.
5
Hyaluronan-mediated motility receptor (RHAMM) immunohistochemical expression and androgen deprivation in normal peritumoral, hyperplasic and neoplastic prostate tissue.透明质酸介导的运动受体 (RHAMM) 的免疫组织化学表达与雄激素剥夺在正常肿瘤周围、增生和肿瘤性前列腺组织中的关系。
BJU Int. 2014 May;113(5):822-9. doi: 10.1111/bju.12339. Epub 2013 Oct 31.
6
Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy.接受长期雄激素剥夺治疗的晚期前列腺癌患者中预测去势抵抗性前列腺癌进展的因素。
BJU Int. 2017 Jan;119(1):74-81. doi: 10.1111/bju.13455. Epub 2016 Mar 23.
7
Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate.首次雄激素剥夺治疗的反应持续时间、去势抵抗性前列腺癌的发生时间以及接受醋酸阿比特龙治疗的转移性去势抵抗性前列腺癌患者的结局。
Anticancer Drugs. 2017 Jan;28(1):110-115. doi: 10.1097/CAD.0000000000000434.
8
Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone.HSD3B1 错义多态性与接受雄激素剥夺治疗或阿比特龙治疗的前列腺癌男性患者结局的相关性。
JAMA Netw Open. 2019 Feb 1;2(2):e190115. doi: 10.1001/jamanetworkopen.2019.0115.
9
[Treatment situation in metastastic Castration Naive Prostate Cancer (mCRPC) and the implications on clinical routine].[转移性去势敏感性前列腺癌(mCRPC)的治疗现状及其对临床常规的影响]
Urologe A. 2019 Sep;58(9):1066-1072. doi: 10.1007/s00120-019-0925-2.
10
Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study.双相雄激素疗法用于初治雄激素剥夺的前列腺癌男性患者:II期蝙蝠侠研究结果
Prostate. 2016 Sep;76(13):1218-26. doi: 10.1002/pros.23209. Epub 2016 Jun 24.

引用本文的文献

1
Metastatic hormone-naïve prostate cancer: a distinct biological entity.转移性去势敏感前列腺癌:一种独特的生物学实体。
Trends Cancer. 2024 Sep;10(9):825-841. doi: 10.1016/j.trecan.2024.06.005. Epub 2024 Jul 23.
2
Androgen Deprivation Freezes Hormone-Sensitive Prostate Cancer Cells in a Reversible, Genetically Unstable Quasi-Apoptotic State, Bursting into Full Apoptosis upon Poly(ADP-ribose) Polymerase Inhibition.去雄激素治疗使激素敏感型前列腺癌细胞处于可逆的、遗传不稳定的类凋亡状态,在多聚(ADP-核糖)聚合酶抑制后会爆发为完全凋亡。
Int J Mol Sci. 2023 Jan 20;24(3):2040. doi: 10.3390/ijms24032040.

本文引用的文献

1
Dynamics of Phenotypic Heterogeneity Associated with EMT and Stemness during Cancer Progression.癌症进展过程中与上皮-间质转化和干性相关的表型异质性动态变化
J Clin Med. 2019 Sep 25;8(10):1542. doi: 10.3390/jcm8101542.
2
Cell death: a review of the major forms of apoptosis, necrosis and autophagy.细胞死亡:细胞凋亡、坏死和自噬的主要形式综述。
Cell Biol Int. 2019 Jun;43(6):582-592. doi: 10.1002/cbin.11137. Epub 2019 Apr 25.
3
Selected Office Based Anticancer Treatment Strategies.选定的基于办公室的抗癌治疗策略。
J Oncol. 2019 Jan 15;2019:7462513. doi: 10.1155/2019/7462513. eCollection 2019.
4
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
5
Prognostic Value of the New Prostate Cancer International Society of Urological Pathology Grade Groups.新的前列腺癌国际泌尿病理学会分级组的预后价值
Front Med (Lausanne). 2017 Sep 29;4:157. doi: 10.3389/fmed.2017.00157. eCollection 2017.
6
Apoptosis and proliferation of the prostate cells in men with benign prostatic hyperplasia and concomitant metabolic disorders.良性前列腺增生合并代谢紊乱患者前列腺细胞的凋亡和增殖。
Histol Histopathol. 2018 Apr;33(4):389-397. doi: 10.14670/HH-11-934. Epub 2017 Sep 26.
7
Newly Proposed Prognostic Grade Group System for Prostate Cancer: Genesis, Utility and its Implications in Clinical Practice.新提出的前列腺癌预后分级组系统:起源、效用及其在临床实践中的意义
Curr Urol Rep. 2016 Nov;17(11):80. doi: 10.1007/s11934-016-0635-x.
8
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.EAU-ESTRO-SIOG 前列腺癌诊治指南。第 1 部分:筛查、诊断及有治愈意图的局部治疗。
Eur Urol. 2017 Apr;71(4):618-629. doi: 10.1016/j.eururo.2016.08.003. Epub 2016 Aug 25.
9
Prostate Cancer Grading: A Decade After the 2005 Modified Gleason Grading System.前列腺癌分级:2005年改良版 Gleason 分级系统发布十年后
Arch Pathol Lab Med. 2016 Oct;140(10):1140-52. doi: 10.5858/arpa.2015-0487-SA. Epub 2016 Jan 12.
10
The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System.2014年国际泌尿病理学会(ISUP)前列腺癌Gleason分级共识会议:分级模式的定义及新分级系统的建议
Am J Surg Pathol. 2016 Feb;40(2):244-52. doi: 10.1097/PAS.0000000000000530.